Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 6:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,781 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Results available

IDH1 Peptide Vaccine for Recurrent Grade II Glioma

NCT02193347
Conditions
Brain Cancer, Brain Neoplasm, Primary, Brain Neoplasms, Recurrent, Brain Tumor, Cancer of the Brain
Interventions
PEPIDH1M vaccine, Tetanus-Diphtheria Toxoid (Td), Temozolomide
Biological · Drug
Lead sponsor
Katy Peters, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Tumor, Solid
Interventions
BDB001 (EIK1001), Atezolizumab
Drug
Lead sponsor
Eikon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Sarasota, Florida • Nashville, Tennessee + 1 more
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions
peripheral blood lymphocyte therapy
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Myeloma, Plasma-Cell, Myeloma-Multiple
Interventions
Cyclophosphamide, Fludarabine, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 73 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cervical Intraepithelial Neoplasia
Interventions
E7 TCR
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Bethesda, Maryland
Active, not recruiting Phase 1 Interventional

T-Cell Therapy for Advanced Breast Cancer

NCT02792114
Conditions
Breast Cancer, Metastatic HER2-negative Breast
Interventions
Cyclophosphamide, Mesothelin-targeted T cells, AP1903
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Hepatocellular Carcinoma, Biliary Tract Cancer
Interventions
RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
12
States / cities
Beverly Hills, California • La Jolla, California • Miami, Florida + 9 more
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab + Poly-ICLC in MRP Colon Cancer

NCT02834052
Conditions
Metastatic Colon Cancer, Solid Tumor
Interventions
pembrolizumab, Poly-ICLC
Drug
Lead sponsor
Asha Nayak
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Small-cell Lung Cancer
Interventions
Carboplatin, Cisplatin, Etoposide, Durvalumab, Stereotactic Body Radiotherapy
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Brooklyn, New York • Flushing, New York • New York, New York
Conditions
Solid Tumor, Adult
Interventions
CF33-CD19 IT Monotherapy, CF33-CD19 IV Monotherapy, CF33-CD19 IT Combination, CF33-CD19 IV Combination, Blinatumomab, Hydroxyurea
Biological · Drug
Lead sponsor
Imugene Limited
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Conditions
Brain and Central Nervous System Tumors
Interventions
therapeutic autologous dendritic cells
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
1 Year to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Non-small Cell Lung Cancer, Carcinoma, NSCLC
Interventions
Ensartinib, Durvalumab
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Conditions
Glioblastoma Multiforme
Interventions
ICT-107, Placebo DC
Biological
Lead sponsor
Precision Life Sciences Group
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
25
States / cities
South Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 17 more
Conditions
Macrophage Activation Syndrome, Primary Hemophagocytic Lymphohistiocytosis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month to 120 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Oropharyngeal Squamous Cell Carcinoma
Interventions
Pembrolizumab, Nivolumab
Drug
Lead sponsor
Hookipa Biotech GmbH
Industry
Eligibility
18 Years and older
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dublin, Ohio
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
Neladalkib (NVL-655), Midazolam, Repaglinide, Itraconazole
Drug
Lead sponsor
Nuvalent Inc.
Industry
Eligibility
12 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
21
States / cities
Orange, California • Sacramento, California • Stanford, California + 16 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver
Interventions
Biopsy, Biospecimen Collection, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging, Transarterial Radioembolization, Yttrium Y 90 Resin Microspheres
Procedure · Biological · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Sasanlimab Prefilled syringe, Encorafenib, Binimetinib, Sasanlimab, Axitinib, SEA-TGT
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
43
States / cities
Duarte, California • Encinitas, California • Fresno, California + 25 more
Conditions
Breast Cancer, HER2-positive Breast Cancer
Interventions
HER2 Vaccine
Drug
Lead sponsor
Pravin T.P Kaumaya
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Melanoma
Interventions
LGX818, MEK162, vemurafenib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
921 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
50
States / cities
Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 33 more
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Interventions
EGFR BATs after standard of care chemo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Interventions
Toripalimab, Carboplatin, Cisplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
Matthew Spector
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Biliary Tract Cancers
Interventions
mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Prostate Cancer
Interventions
Aglatimagene besadenovec + valacyclovir, Placebo + valacyclovir
Biological
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2030
U.S. locations
72
States / cities
Gilbert, Arizona • Glendale, Arizona • Peoria, Arizona + 56 more